Category: Patent & Other IP Offices
-
USPTO director Squires greenlights deputy Morgan Stewart’s PTAB discretionary denial program
John A. Squires, who took over as United States Patent and Trademark Office director last month, has issued a Delegation of Authority for deputy director Coke Morgan Stewart to continue the recently reinstated Patent Trial and Appeal Board discretionary denial program.
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Office’s Patent Trial and Appeal Board decision that deemed one of Bayer’s rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
Novo Nordisk suffers loss over negative claim limitation in ongoing patent dispute over diabetes drug Wegovy
The United States District Court for the District of Delaware has ruled that Viatris has not induced the infringement of one of five asserted patents in litigation initiated by Novo Nordisk.
-
UK government proposes SEP measures such as rate-setting procedure, seeks input
The UK Intellectual Property Office has invited stakeholders from across the SEP ecosystem to submit views and evidence on proposed SEP measures by October 7, 2025.
-
USPTO divisions’ clash over Apple patent invalidation decision undermines “integrity and consistency”, patentee alleges
A petition filed by Proxense against Apple has uncovered an inconsistency in results on substantially similar issues and the same underlying facts between decisions by the United States Patent & Trademark Office’s Patent Trial and Appeal Board and fellow internal division, the Central Reexamination Unit.
-
EPO’s Enlarged Board of Appeal: reproducibility irrelevant to eligibility of sold product as prior art and ability to destroy novelty
Context: The Enlarged Board of Appeal (EBA) of the European Patent Office (EPO) made a decision on claim construction last month that aligns its case law with that of the Unified Patent Court’s (UPC) Court of Appeal (CoA) (June 18, 2025 ip fray article). We will continue to report on EBA decisions that we believe…
-
USPTO issues more discretionary denials: Intel, Google, Nokia, Ericsson among losing petitioners
The significant inter partes review denials come less than a month after a Unified Patents report found the number of such decisions is three times higher than those under Director Andrei Iancu in 2020.
-
European Patent Office aligns with Unified Patent Court on claim construction standard: Enlarged Board of Appeal decision
Today’s decision by a Board of Appeal of the European Patent Office lays out a claim construction standard that is materially consistent with that of the Unified Patent Court’s Court of Appeal.
-
USPTO on pace to quadruple discretionary denials under new interim procedures, report says
Recent data by Unified Patents has found that there were three times more United States Patent & Trademark Office’s Patent Trial and Appeal Board discretionary denial decisions in Q1 2025 than the last record number of decisions (167 in 2020).
-
Pendulum swings back in favor of Fintiv in payment-system patent infringement dispute with Apple
The United States Court of Appeals for the Federal Circuit has reversed a Western District of Texas grant of summary judgment in a dispute between Fintiv and Apple, reviving Fintiv’s infringement claims and remanding them for trial.